Eric Aboagye: "Imagen molecular y radiómica en la investigación del cáncer: aplicaciones a la oncología de precisión"

21/03/2019

Dr Eric Aboagye holds the position of Professor of Cancer Pharmacology and Molecular Imaging at Imperial College London, where he is Director of the Cancer Imaging Centre. Dr Aboagyes primary research interest is in the field of molecular imaging: discovery,development and application of molecular imaging methods, particularly positron emission tomography, to study tumour biology and novel therapies. Working at the interface of chemistry, mathematics, and biology, he has made fundamental discoveries in visualising complex cancer processes in living subjects, and translated these methods to provide advanced tools for detecting drug distribution and consequences of drug-target modulation in humans, as well as tools for early disease detection and objective response assessment. His research group is well known internationally for developing methodologies that permit visualisation and quantification of core tumour biologic phenotypes including cell proliferation, apoptosis, angiogenesis, hypoxia, and growth factorreceptor signalling. More recently his team has also developed imaging tools to enable better characterisation of choline, glycogen and fatty acid metabolism. Mathematical modelling approaches for tracer kinetics and texture analysis have been developed and applied hand-in-hand with the chemical-biology approaches. He received British Institute of Radiology Sir Mackenzie Davidson Medal in 2009 and was elected to fellowship of the United Kingdom Academy of Medical Sciences in 2010. He is author of over 220 publications and 12 patents on cancer drug development and imaging and has contributed to the early careers of excellent researchers including 22 PhD students who have graduated under his primary supervision and 37 post-doctoral fellows primarily mentored by him; several of these researchers have established their own research groups. Dr Aboagye has acted as an Advisor to international pharmaceutical and Imagi companies including GE Healthcare, LightPoint, GSK, Roche and Novartis Pharmaceuticals.

Vídeos
Ciencias de la vida y de la materia Oncología personalizada de precisión

Eduardo Díaz Rubio: "Lección Magistral: Estrategias de tratamiento en oncología: una perspectiva histórica"

21/03/2019

02carlosarteaga.mp4

Rafael Rosell: "Nuevas dianas terapéuticas en cáncer de pulmón"

21/03/2019

Patrick Tan: "Alteraciones epigenómicas en cánceres endémicos en Asia"

21/03/2019

Manuel Hidalgo: "Nuevos abordajes terapéuticos en cáncer de páncreas"

21/03/2019

Florian Markowetz: "Procesos mutacionales que modulan el número de copias de los genomas del cáncer"

21/03/2019

Santiago Ramón y Cajal: "Heterogeneidad intratumoral: cómo identificarla"

21/03/2019

Pier Paolo Pandolfi: "Reactivación de supresores tumorales en la prevención y terapia del cáncer"

21/03/2019

Enzo Medico: "Oncogenómica y modelos preclínicos derivados del paciente para la medicina de precisión del cáncer colorrectal"

21/03/2019

Ignacio Melero: "La búsqueda de eficacia y de biomarcadores en inmuno-oncología"

21/03/2019

Eric Aboagye: "Imagen molecular y radiómica en la investigación del cáncer: aplicaciones a la oncología de precisión"

21/03/2019

Felipe Calvo: "Radioterapia en la oncología de precisión"

21/03/2019

José Martínez Olmos: "La oncología personalizada de precisión en el Sistema Nacional de Salud"

21/03/2019

Fernando Bandrés: "Consideraciones éticas y legales en la medicina de precisión"

21/03/2019

Paul Workman: "Futuro y sostenibilidad de la investigación en oncología de precisión"

21/03/2019